S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
Secure your stake in the Smart Home industry. (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
Secure your stake in the Smart Home industry. (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
Secure your stake in the Smart Home industry. (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
Secure your stake in the Smart Home industry. (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
Secure your stake in the Smart Home industry. (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
Secure your stake in the Smart Home industry. (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
Secure your stake in the Smart Home industry. (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
Secure your stake in the Smart Home industry. (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners

Checkpoint Therapeutics (CKPT) Stock Forecast & Price Target

$2.41
+0.14 (+6.17%)
(As of 11/28/2023 ET)
Compare
Today's Range
$2.21
$2.48
50-Day Range
$1.39
$2.41
52-Week Range
$1.30
$8.15
Volume
630,309 shs
Average Volume
274,077 shs
Market Capitalization
$56.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.80

Checkpoint Therapeutics Consensus Analyst Rating and Stock Price Forecast (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 5 Analyst Ratings

Analysts' Consensus Price Target

$24.80
929.05% Upside
High Forecast$47.00
Average Forecast$24.80
Low Forecast$14.00
TypeCurrent Forecast
11/29/22 to 11/29/23
1 Month Ago
10/30/22 to 10/30/23
3 Months Ago
8/31/22 to 8/31/23
1 Year Ago
11/29/21 to 11/29/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$24.80$24.80$24.80$197.50
Predicted Upside929.05% Upside888.84% Upside888.84% Upside934.03% Upside
Get Checkpoint Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter.


CKPT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CKPT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Checkpoint Therapeutics Stock vs. The Competition

TypeCheckpoint TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.67
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside929.05% Upside1,021.05% Upside2,838.33% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/16/2023Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$16.00 ➝ $14.00+593.07%
8/15/2023LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$65.00 ➝ $47.00+2,148.79%
8/15/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$19.00 ➝ $14.00+569.85%
8/4/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$34.00+1,365.51%
12/19/2022B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$7.00 ➝ $15.00+273.13%
(Data available from 11/29/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












CKPT Price Target - Frequently Asked Questions

What is Checkpoint Therapeutics's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for Checkpoint Therapeutics stock is Buy based on the current 5 buy ratings for CKPT. The average twelve-month price prediction for Checkpoint Therapeutics is $24.80 with a high price target of $47.00 and a low price target of $14.00. Learn more on CKPT's analyst rating history.

Do Wall Street analysts like Checkpoint Therapeutics more than its competitors?

Analysts like Checkpoint Therapeutics more than other Medical companies. The consensus rating for Checkpoint Therapeutics is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how CKPT compares to other companies.

Does Checkpoint Therapeutics's stock price have much upside?

According to analysts, Checkpoint Therapeutics's stock has a predicted upside of 888.84% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

This page (NASDAQ:CKPT) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -